Discontinued — last reported Q4 '22
Interest Income
Alnylam Pharmaceuticals Interest Income decreased by 0.1% to $26.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.2%, from $28.67M to $26.60M. Over 4 years (FY 2021 to FY 2025), Interest Income shows an upward trend with a 189.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher interest income suggests a strong cash position or a favorable interest rate environment for the company's investments.
Detailed definition
Interest income is the revenue earned from cash deposits, marketable securities, and other interest-bearing investments....
Peer comparison
Varies based on cash management strategies; companies with large cash piles will report higher interest income than those with high debt.
interest_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $409.00K | $225.00K | $495.00K | $1.01M | $1.90M | $7.82M | $14.08M | $18.66M | $21.08M | $25.43M | $30.41M | $29.65M | $29.18M | $32.15M | $31.02M | $28.67M | $27.49M | $28.68M | $26.63M | $26.60M |
| QoQ Change | — | -45.0% | +120.0% | +104.4% | +87.6% | +311.8% | +80.0% | +32.5% | +13.0% | +20.6% | +19.6% | -2.5% | -1.6% | +10.2% | -3.5% | -7.6% | -4.1% | +4.3% | -7.2% | -0.1% |
| YoY Change | — | — | — | — | +364.3% | >999% | >999% | >999% | >999% | +225.1% | +116.0% | +58.9% | +38.5% | +26.4% | +2.0% | -3.3% | -5.8% | -10.8% | -14.1% | -7.2% |
Interest Income at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest income?
- Alnylam Pharmaceuticals (ALNY) reported interest income of $26.60M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest income changed year-over-year?
- Alnylam Pharmaceuticals's interest income decreased by 7.2% year-over-year, from $28.67M to $26.60M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest income has grown at a 189.9% compound annual growth rate (CAGR), from $1.58M to $111.47M.
- What does interest income mean?
- The money earned from interest on cash holdings and investments.